I would say Bendeka has a 75% chance of getting ODE (and hence seven years of protection from US generic competition); however, FDA decisions on ODE do not have a formal deadline, so I can’t say when the decision will come.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.